These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12785235)

  • 1. [Effects of angiotensin receptor inhibitors on cardiovascular endpoints--current and future evidence].
    Karlócai K
    Orv Hetil; 2003 May; 144(18 Suppl 1):901-3. PubMed ID: 12785235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angiotensin converting enzyme inhibitors in arterial hypertension].
    Ramón González-Juanatey J
    Rev Esp Cardiol; 1999; 52 Suppl 3():73-8. PubMed ID: 10614152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Regression of left ventricular hypertrophy in hypertensive patients].
    Bosa Ojeda F; García González M; Domínguez Rodríguez A; Barragán Acea A; Miralles Ibarra JM; Lacalzada Almeida J; de Armas Trujillo D
    Rev Esp Cardiol; 1997; 50 Suppl 4():74-6. PubMed ID: 9411592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of cilazapril in patients with essential hypertension: effect on cardiac hypertrophy].
    Abrahám G; Pogátsa-Murray G; Forster T; Csanády M; Sonkodi S
    Orv Hetil; 1996 Jul; 137(29):1583-6. PubMed ID: 8757070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect.
    Grandi AM; Laurita E; Solbiati F; Marchesi C; Maresca AM; Nicolini E; Guasti L; Venco A
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):207-11. PubMed ID: 17110802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of ACE inhibition on left ventricular hypertrophy.
    Agabiti-Rosei E; Muiesan ML
    Br J Clin Pract Suppl; 1996 Jul; 84():17-22. PubMed ID: 8994997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors].
    He H; Li LM; Cao WH; Liu MZ; Sun NL; Lü J; Hu YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep; 25(9):756-60. PubMed ID: 15555355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of antihypertensive treatment on target organs].
    Fregoso Padilla J
    Arch Cardiol Mex; 2002; 72 Suppl 1():S58-63. PubMed ID: 12001872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardioprotective and cardio-reparative drugs].
    Bolaños F
    Rev Esp Cardiol; 1997; 50 Suppl 4():53-6. PubMed ID: 9411588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.